X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
0
Other Certificates
0
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-june-7-2023-80553.pdf
https://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-announces-divestment-of-dsuvia-to-alora-pharmaceuticals-301771123.html
https://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-announces-peer-reviewed-publication-on-the-use-of-dsuvia-for-in-office-rhinology-procedures-301759253.html
https://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-announces-abstract-acceptance-for-podium-presentation-at-the-anesthesiology-2022-annual-meeting-301603228.html
https://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-announces-publication-of-results-from-an-investigator-initiated-trial-on-sufentanil-sublingual-tablet-sst-compared-to-standard-intravenous-opioids-during-plastic-surgery-procedures-performed-under-general--301543161.html
https://www.prnewswire.com/news-releases/minimal-side-effects-and-short-recovery-time-reported-for-dsuvia-treated-patients-plastic-surgery-podium-presentation-at-the-aesthetic-meeting-2022-301531621.html
https://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-announces-publication-of-an-editorial-by-an-internationally-recognized-leader-in-opioid-sparing-surgery-highlighting-the-potential-advantages-of-the-sufentanil-sublingual-tablet-in-joint-replacement-surgery-301459074.html
https://www.prnewswire.com/news-releases/presentation-on-the-effect-of-the-administration-of-sufentanil-sublingual-tablet-on-reducing-post-operative-recovery-time-and-opioid-use-in-plastic-surgery-at-the-annual-miami-cosmetic-surgery-event-301363317.html
https://www.fiercepharma.com/marketing/fda-rips-flippant-tongue-and-done-promo-for-potent-opioid-drug-dsuvia-from-acelrx
https://www.fda.gov/drugs/drug-safety-and-availability/fda-issues-warning-acelrx-m[…]ing-false-and-misleading-claims-about-risks-and-benefits-dsuvia
https://www.prnewswire.com/news-releases/acelrx-awarded-us-army-contract-for-dsuvia-301135341.html#:~:text=(Nasdaq%3A%20ACRX)%2C%20(,the%20purchase%20of%20DSUVIA%20to
https://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-to-present-at-the-jefferies-virtual-healthcare-conference-301068872.html
https://www.reuters.com/article/brief-acelrx-says-grnenthal-gmbh-said-it-idUSFWN2D40LD
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-january-22-2020-1579699881.pdf
https://www.prnewswire.com/news-releases/acelrx-announces-the-closing-of-a-25-million-senior-secured-debt-facility-300860261.html
https://www.raps.org/news-and-articles/news-articles/2019/3/public-citizen-fda-advisor-call-for-moratorium-on
https://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-sufentanil-sublingual-tablet-dsuvia-to-be-highlighted-during-a-presentation-at-the-boswick-burn-and-wound-symposium-300787332.html
https://endpts.com/fda-opioid-adcomm-chair-blasts-agency-for-willful-blindness-that-borders-on-the-criminal/
https://thehill.com/opinion/healthcare/416282-new-fda-approved-synthetic-opioid-serves-a-good-purpose
https://www.fiercepharma.com/pharma/acelrx-s-controversial-under-tongue-opioid-nod-sparks-rare-defense-from-fda-chief
https://www.reuters.com/article/us-acelrx-pharma-fda/fda-approves-acelrx-pharmas-opioid-pain-drug-idUSKCN1N727J
https://endpts.com/trevena-gets-hammered-again-as-the-fda-formally-spurns-their-controversial-marketing-application/
https://abcnews.go.com/Health/dsuvia-opioid-painkiller/story?id=58875487
https://www.buzzfeednews.com/article/danvergano/dsuvia-sufentanil-fda-vote?ref=bfnsplash&utm_term=4ldqpho
https://www.biospace.com/article/with-opioid-abuse-in-mind-fda-advisory-committee-recommends-acelrx-s-opioid-dsuvia/
http://www.pharmafile.com/news/519070/fda-advisory-panel-approves-acelrxs-opioid-pain-drug-dsuvia
https://endpts.com/experts-offer-a-solid-endorsement-for-acelrx-pain-med-spurring-a-big-rally-for-their-stock/
https://www.fiercebiotech.com/biotech/1-year-after-fda-snub-adcomm-recommends-acelrx-s-dsuvia-for-approval-10-3
https://www.reuters.com/article/us-acelrx-pharma-fda/acelrx-shares-surge-after-fda-staff-says-opioid-safe-idUSKCN1MK1MZ
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004335/human_med_002265.jsp&mid=WC0b01ac058001d124
http://www.pharmatimes.com/news/eu_approval_for_acelrx_dzuveo_1242324
https://www.prnewswire.com/news-releases/acelrx-resubmits-new-drug-application-for-dsuvia-300645139.html
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-february-14-2018-1518587433.pdf
http://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-appoints-vincent-j-angotti-chief-executive-officer-300409117.html
https://www.pharmacompass.com/pdf/news/us-fda-enforcement-report-16mar2016-1458126358.pdf
http://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-presents-phase-3-results-from-arx-04-clinical-program-at-jab-burn-and-wound-care-symposium-300217201.html
http://www.prnewswire.com/news-releases/acelrx-completes-protocol-review-with-fda-and-plans-to-initiate-phase-3-open-label-study-iap312-for-zalviso-in-1q-2016-300201382.html
https://www.pharmacompass.com/pdf/news/acelrx-pharmaceuticals-zalviso-approved-in-eu-for-post-operative-pain-1443869122.pdf
http://www.prnewswire.com/news-releases/pdl-biopharma-acquires-a-portion-of-acelrx-pharmaceuticals-expected-royalties-and-commercial-milestones-from-zalviso-for-65-million-300145966.html
http://www.fiercebiotech.com/story/stymied-fda-acelrx-claims-success-phiii-pain-study/2015-09-09?utm_medium=rss&utm_source=rss&utm_campaign=rss
http://www.fiercebiotech.com/story/acelrx-hammered-again-after-fda-demands-new-zalviso-study-after-all/2015-03-09
http://phx.corporate-ir.net/phoenix.zhtml?c=121590&p=irol-newsArticle&ID=1999710
Market Place
Share 
